A stock in the biotechnology and drugs complex that's nearing a big breakout is Halozyme Therapeutics (HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. This stock is out the gate strong in 2102, with shares up over 11%.
If you look at the chart for Halozyme Therapeutics, you'll see that stock has been uptrending strong since it found big buying support back in October at around $5.60 a share. During the recent uptrend, this stock has been consistently making higher lows and higher highs, which is bullish price action. Now the stock is rapidly approaching a big breakout if it can manage to clear some near-term overhead resistance.
Market players should put HALO on their trading radar for a sustained high-volume move and close above $10.88 to $11 a share. Look for volume that registers near or above its three-month average action of 633,324 shares. At last check, HALO hit $11 a share today and the volume is just 100,000 shares short of that average action. I would consider any high-volume move over $10.88 to $11 a share to be very bullish since it will push HALO into all-time high territory. Momentum money could easily pile into this stock off a high-volume close over $11.You could simply be a buyer of HALO once it closes over $10.88 to $11 a share with volume. I would simply use a mental stop that's a few percentage points below $10.88 in case the breakout fails. You could also use a stop a bit lower near some previous support at $10.05. I am looking for a sizeable spike higher by 10% or more if this stock can enter all-time high territory with strong volume. I also featured Halozyme earlier this month in "5 Stocks Hitting New 52-Week Highs."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV